河北医学
河北醫學
하북의학
HEBEI MEDICINE
2015年
8期
1400-1402
,共3页
奥美拉唑%兰索拉唑%药物经济学%胃溃疡%幽门螺杆菌
奧美拉唑%蘭索拉唑%藥物經濟學%胃潰瘍%幽門螺桿菌
오미랍서%란색랍서%약물경제학%위궤양%유문라간균
Omeprazole%Lansoprazole%Pharmacoeconomics%Stomach ulcer%Helicobacter pylori
目的：应用药物经济学原理分析奥美拉唑与兰索拉唑治疗幽门螺旋杆菌（ Hp ）阴性胃溃疡成本－效果，为合理用药提供科学依据。方法：选择符合标准的患者87例，分为奥美拉唑组44例和兰索拉唑组43例，疗程结束时评价临床效果及成本－效果。结果：奥美拉唑组患者治愈23例、显效9例、有效5例、无效7例，总有效率84．09％；兰索拉唑组患者治愈24例、显效10例、有效4例、无效5例，总有效率88．37％，差异无统计学意义（χ2＝0．335，P＝0．563）。奥美拉唑组C／E为0．46，低于兰索拉唑组的1．99，△C／△E为89．65，差异具有统计学意义（ P＜0．05）。敏感度分析示奥美拉唑组C／／E为0．41，低于兰索拉唑组的1．79，ΔC／／ΔE为89．45，差异具有统计学意义（ P＜0．05）。奥美拉唑组不良反应发生率4．55％，与兰索拉唑组6．98％相似，差异无统计学意义（ P＞0．05）。结论：奥美拉唑治疗Hp阴性胃溃疡具有更高的药物经济学价值，可减少医疗资源浪费。
目的：應用藥物經濟學原理分析奧美拉唑與蘭索拉唑治療幽門螺鏇桿菌（ Hp ）陰性胃潰瘍成本－效果，為閤理用藥提供科學依據。方法：選擇符閤標準的患者87例，分為奧美拉唑組44例和蘭索拉唑組43例，療程結束時評價臨床效果及成本－效果。結果：奧美拉唑組患者治愈23例、顯效9例、有效5例、無效7例，總有效率84．09％；蘭索拉唑組患者治愈24例、顯效10例、有效4例、無效5例，總有效率88．37％，差異無統計學意義（χ2＝0．335，P＝0．563）。奧美拉唑組C／E為0．46，低于蘭索拉唑組的1．99，△C／△E為89．65，差異具有統計學意義（ P＜0．05）。敏感度分析示奧美拉唑組C／／E為0．41，低于蘭索拉唑組的1．79，ΔC／／ΔE為89．45，差異具有統計學意義（ P＜0．05）。奧美拉唑組不良反應髮生率4．55％，與蘭索拉唑組6．98％相似，差異無統計學意義（ P＞0．05）。結論：奧美拉唑治療Hp陰性胃潰瘍具有更高的藥物經濟學價值，可減少醫療資源浪費。
목적：응용약물경제학원리분석오미랍서여란색랍서치료유문라선간균（ Hp ）음성위궤양성본－효과，위합리용약제공과학의거。방법：선택부합표준적환자87례，분위오미랍서조44례화란색랍서조43례，료정결속시평개림상효과급성본－효과。결과：오미랍서조환자치유23례、현효9례、유효5례、무효7례，총유효솔84．09％；란색랍서조환자치유24례、현효10례、유효4례、무효5례，총유효솔88．37％，차이무통계학의의（χ2＝0．335，P＝0．563）。오미랍서조C／E위0．46，저우란색랍서조적1．99，△C／△E위89．65，차이구유통계학의의（ P＜0．05）。민감도분석시오미랍서조C／／E위0．41，저우란색랍서조적1．79，ΔC／／ΔE위89．45，차이구유통계학의의（ P＜0．05）。오미랍서조불량반응발생솔4．55％，여란색랍서조6．98％상사，차이무통계학의의（ P＞0．05）。결론：오미랍서치료Hp음성위궤양구유경고적약물경제학개치，가감소의료자원낭비。
Objective:To analyze the cost-effectiveness ratios of omeprazole and lansoprazole in treat-ment of Helicobacter pylori ( Hp) -negative stomach ulcer by pharmacoeconomics principles, and to provide scientific foundations for rational use of drug.Method:A total of 87 eligible patients were selected and divid-ed into omeprazole group (44 patients) and lansoprazole group (43 patients).At the end of treatment, the cost-effectiveness ratios and clinical effect were evaluated.Result: Of the omeprazole group, 23 patients were cured, 9 patients were responsive to the treatment excellently, 5 patients were responsive to the treat-ment, and 7 patients were unresponsive to the treatment, and the total effective rate was 84.09%; while of the lansoprazole group, 24 patients were cured, 10 patients were responsive to the treatment excellently, 4 patients were responsive to the treatment, and 5 patients were unresponsive to the treatment, and the total ef-fective rate was 88.37%;and the difference was statistically insignificant (χ2=0.335, P=0.563) .The C/E of the omeprazole group was 0.46, which was lower than that of the lansoprazole group (1.99), the△C/△E was 89.65, and the difference was statistically significant ( P<0.05) .Sensitivity analysis showed the C//E of the omeprazole group was 0.41,which was lower than that of the lansoprazole group (1.79), the ΔC//ΔE was 89.45, and the difference was statistically significant (P<0.05).The incidence of adverse reactions of the omeprazole group was 4.55%, was similar to the lansoprazole group ( 6.98%) , and the difference was statistically insignificant ( P>0.05) .Conclusion:Omeprazole in treatment of Hp-negative stomach ulcer has higher pharmacoeconomics values, and can reduce medical resources waste.
